Clinical Research Of Bortezomib Therapy In Multiple Myelomaa

Objective: To study the efficacy and adverse reactions of Bortezomib in the treatment of multiple myeloma(MM).Methods: Twenty-nine patients with multiple myeloma received Bortezomib at 1.3mg/m2.Results:29 patients receiving the chemotherapy,19 patients were newly diagnosed and 11 patients were relapsed or refractory.The total effective rate was 89.65%(26/29),the CR rate was 27.58%(8/29).The total effective of newly diagnosed patients rate was 100%(19/19),of which CR 8 cases,6 cases of VGPR,5 cases of PR.The total effective of relapsed or refractory patients rate was 91%(7/10),of which 3 cases of VGPR,4 cases of PR,2 cases of SD,1case of PD.The main adverse reactions include digestive system adverse reactions,blood system disease,peripheral neuropathy,and the symptom such as lung infection,herpes zoster,the corresponding drugs can be improved after symptomatic treatment.Conclusion: For the newly diagnosed and relapsed or refractory multiple myeloma patients,Bortezomib a safe and effective therapeutic drugs with rapid onset,high treatment response rate and complete remission rate.